Villere ST Denis J & Co. LLC trimmed its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 2.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 133,085 shares of the company's stock after selling 3,334 shares during the quarter. Villere ST Denis J & Co. LLC's holdings in Johnson & Johnson were worth $20,329,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also made changes to their positions in the company. Horizon Bancorp Inc. IN lifted its holdings in shares of Johnson & Johnson by 11.2% during the second quarter. Horizon Bancorp Inc. IN now owns 636 shares of the company's stock valued at $97,000 after purchasing an additional 64 shares during the last quarter. Global Strategic Investment Solutions LLC lifted its holdings in shares of Johnson & Johnson by 3.5% during the second quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company's stock valued at $294,000 after purchasing an additional 65 shares during the last quarter. JSF Financial LLC lifted its holdings in shares of Johnson & Johnson by 2.2% during the second quarter. JSF Financial LLC now owns 2,993 shares of the company's stock valued at $457,000 after purchasing an additional 65 shares during the last quarter. Elios Financial Group Inc. lifted its holdings in shares of Johnson & Johnson by 1.5% during the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock valued at $746,000 after purchasing an additional 66 shares during the last quarter. Finally, Atlantic Family Wealth LLC lifted its holdings in shares of Johnson & Johnson by 4.4% during the first quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock valued at $266,000 after purchasing an additional 67 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
JNJ has been the subject of several analyst reports. The Goldman Sachs Group upped their target price on Johnson & Johnson from $186.00 to $212.00 and gave the company a "buy" rating in a report on Thursday. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Barclays upped their price target on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Royal Bank Of Canada reissued an "outperform" rating and set a $209.00 price target on shares of Johnson & Johnson in a research report on Friday. Finally, Bank of America upped their price target on Johnson & Johnson from $175.00 to $198.00 and gave the company a "neutral" rating in a research report on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $192.94.
Get Our Latest Stock Analysis on Johnson & Johnson
Insiders Place Their Bets
In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by insiders.
Johnson & Johnson Stock Performance
Shares of JNJ stock opened at $190.66 on Monday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $192.10. The stock's 50-day moving average is $178.48 and its two-hundred day moving average is $163.78. The firm has a market cap of $459.16 billion, a P/E ratio of 20.39, a PEG ratio of 2.40 and a beta of 0.40.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $24.02 billion for the quarter. Analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is presently 55.61%.
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
